# The trials designed to test cagrilintide on its own

- Article ID: research-055
- Product: Cagrilintide (cagrilintide-701)
- Canonical page: https://heritagebiolabs.com/research-library/articles/055-the-trials-designed-to-test-cagrilintide-on-its-own
- Product collection: https://heritagebiolabs.com/research-library/products/cagrilintide
- Product page: https://heritagebiolabs.com/product/cagrilintide-701
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2025, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids joined by peptide bonds. Some mimic hormones that carry information about nutrients and fullness. Cagrilintide is an investigational, long-acting peptide that activates receptors for amylin and calcitonin. It is often discussed alongside semaglutide because they are being studied together as CagriSema. Several registry records updated in 2026 show how researchers are studying cagrilintide separately. [1, 2, 3]

Two trials called RENEW compare cagrilintide with placebo over a 64-week treatment period. One enrolls people with excess body weight, and the other specifically enrolls people who also have type 2 diabetes. Both use relative change in body weight as a primary measure. By putting the studies in different populations, researchers can examine outcomes in people whose underlying metabolic conditions and background care may differ. The records identify the assigned interventions and the planned measurements. [2, 3]

A separate study first posted in August 2026 compares two presentations of cagrilintide with placebo. Its primary weight measurement is planned for 26 weeks. A comparison of presentations can help determine whether preparations intended to deliver the same active peptide have comparable observed effects under the trial conditions. That is a narrower question than how one active ingredient compares with a drug that acts on another receptor. [1]

The entries available by November 8, 2026 list no posted results for these three studies. They show that the research program includes placebo-controlled tests of cagrilintide itself and a comparison of its presentations. Estimates of benefit and adverse events will depend on actual outcomes in the participants and how completely investigators are able to report them. [1, 2, 3]

## Sources

1. Novo Nordisk A/S. A Placebo-controlled Comparability Study to Compare Two Presentations of Cagrilintide for Weight Management in Participants With Overweight or Obesity. ClinicalTrials.gov (publication 2026-08-04, record updated 2026-09-04). <https://clinicaltrials.gov/study/NCT07745504>
2. Novo Nordisk A/S. Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity and Type 2 Diabetes. ClinicalTrials.gov (publication 2025-10-24, record updated 2026-10-07). <https://clinicaltrials.gov/study/NCT07220759>
3. Novo Nordisk A/S. Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity. ClinicalTrials.gov (publication 2025-10-24, record updated 2026-08-06). <https://clinicaltrials.gov/study/NCT07220642>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 011 - BPC-157 TB-500 and Cagrilintide.docx; article 55; content SHA-256 c9c1ebd01708db7551630deea85b2ece9b4ab199e328e3cf7026a19ba43054e0.
